journal
MENU ▼
Read by QxMD icon Read
search

Thoracic Cancer

journal
https://www.readbyqxmd.com/read/27910227/preoperative-computed-tomography-diagnosis-of-non-recurrent-laryngeal-nerve-in-patients-with-esophageal-carcinoma
#1
Zhong-Xi Niu, Hang Zhang, Long-Qi Chen, Hui Shi, Jun Peng, Li-Wei Su, Wei Li, Bo Xiao, Shu He, Hong-Xu Yue
BACKGROUND: The non-recurrent laryngeal nerve (NRLN) is a rare but potentially serious anomaly that is commonly associated with the aberrant right subclavian artery (ARSA). It is easy to damage during surgical resection of esophageal cancer, leading to severe complications. METHODS: Preoperative enhanced thoracic computed tomography (CT) scans of 2697 patients with esophageal carcinoma treated in our hospital between January 2010 and December 2013 were examined...
December 2, 2016: Thoracic Cancer
https://www.readbyqxmd.com/read/27883280/phase-i-study-of-irinotecan-for-previously-treated-lung-cancer-patients-with-the-ugt1a1-28-or-6-polymorphism-results-of-the-lung-oncology-group-in-kyushu-logik1004a
#2
Minoru Fukuda, Midori Shimada, Takeshi Kitazaki, Seiji Nagashima, Kohji Hashiguchi, Noriyuki Ebi, Koichi Takayama, Yoichi Nakanishi, Hiroshi Semba, Taishi Harada, Takashi Seto, Isamu Okamoto, Yukito Ichinose, Kenji Sugio
BACKGROUND: Various polymorphisms have been detected in the UDP-glucuronosyltransferase 1A ( UGT1A ) gene, and UGT1A1 *28 and UGT1A1 *6 have important effects on the pharmacokinetics of irinotecan and the risk of severe toxicities during irinotecan therapy. This study was conducted to determine the maximum tolerated dose (MTD) of irinotecan chemotherapy according to the UGT1A1 genotype in previously treated lung cancer patients with the UGT1A1 *28 or UGT1A1 *6 polymorphism. METHODS: The eligibility criteria were as follows: lung cancer patients that had previously been treated with anticancer agents other than irinotecan, possessed the UGT1A1 *28 or UGT1A1 *6 polymorphism (group A included *28/*28, *6/*6, and *28/*6, and group B included *28 /- and *6 /-), were aged ≤75 years old, had a performance score of 0-1, and exhibited adequate bone marrow function...
November 24, 2016: Thoracic Cancer
https://www.readbyqxmd.com/read/27878984/sulforaphane-induced-apoptosis-in-xuanwei-lung-adenocarcinoma-cell-line-xwlc-05
#3
Lan Zhou, Qian Yao, Yan Li, Yun-Chao Huang, Hua Jiang, Chuan-Qiong Wang, Lei Fan
BACKGROUND: Xuanwei district in Yunnan Province has the highest incidence of lung cancer in China, especially among non-smoking women. Cruciferous vegetables can reduce lung cancer risk by prompting a protective mechanism against respiratory tract inflammation caused by air pollution, and are rich in sulforaphane, which can induce changes in gene expression. We investigated the effect of sulforaphane-induced apoptosis in Xuanwei lung adenocarcinoma cell line (XWCL-05) to explore the value of sulforaphane in lung cancer prevention and treatment...
November 23, 2016: Thoracic Cancer
https://www.readbyqxmd.com/read/27813328/depleted-aldehyde-dehydrogenase-1a1-aldh1a1-reverses-cisplatin-resistance-of-human-lung-adenocarcinoma-cell-a549-ddp
#4
Yunyan Wei, Shuangshuang Wu, Wei Xu, Yan Liang, Yue Li, Weihong Zhao, Jianqing Wu
BACKGROUND: Cisplatin is the standard first-line chemotherapeutic agent for the treatment of non-small cell lung cancer (NSCLC). However, resistance to chemotherapy has been a major obstacle in the management of NSCLC. Aldehyde dehydrogenase 1A1 (ALDH1A1) overexpression has been observed in a variety of cancers, including lung cancer. The purpose of this study was to investigate the effect of ALDH1A1 expression on cisplatin resistance and explore the mechanism responsible. METHODS: Reverse transcriptase-PCR was applied to measure the messenger RNA expression of ALDH1A1, while Western blot assay was employed to evaluate the protein expression of ALDH1A1, B-cell lymphoma 2, Bcl-2-like protein 4, phospho-protein kinase B (p-AKT) and AKT...
November 4, 2016: Thoracic Cancer
https://www.readbyqxmd.com/read/27801981/heterogeneity-of-the-resistance-to-gefitinib-treatment-in-a-non-small-cell-lung-cancer-patient-with-active-epidermal-growth-factor-receptor-mutation
#5
Chong-Rui Xu, Wen-Zhao Zhong, Qing Zhou, Xu-Chao Zhang, Jin-Ji Yang, Yi-Long Wu
We report the case of a 37-year-old male non-small cell lung cancer patient with an active epidermal growth factor receptor (EGFR) mutation who received gefitinib as first-line treatment. After 13.7 months, the patient experienced disease progression and was treated with platinum-based doublet chemotherapy plus gefitinib for 5.4 months. A subsequent lung biopsy showed cMET overexpression; therefore, the patient received a cMET inhibitor with the gefitinib. The response in the different lesions of several organs was diverse...
November 1, 2016: Thoracic Cancer
https://www.readbyqxmd.com/read/27779369/analysis-of-clinical-characteristics-and-prognosis-of-patients-with-anaplastic-lymphoma-kinase-positive-and-surgically-resected-lung-adenocarcinoma
#6
Hong Tao, Yiran Cai, Liang Shi, Junfang Tang, Zhidong Liu, Zitong Wang, Lianqi Bai, Zhe Liu
BACKGROUND: Recent research into lung cancer-related driver genes has identified a distinctive molecular subtype of non-small cell lung cancer (NSCLC) - anaplastic lymphoma kinase (ALK)-positive NSCLC. We evaluated the clinical features and survival rates of ALK-positive lung adenocarcinoma patients who had undergone surgery but had not received ALK inhibitor therapy, along with the characteristics of patients with distant metastases. METHODS: Clinical data of 40 patients with ALK-positive, postsurgical lung adenocarcinoma were retrospectively analyzed...
October 24, 2016: Thoracic Cancer
https://www.readbyqxmd.com/read/27755805/left-bronchial-isomerism-in-a-lung-cancer-patient-undergoing-right-upper-pulmonary-lobectomy-via-a-thoracoscope
#7
Lijian Huang, Lufeng Zhao, Hu Tang, Ying Chai
Left bronchial isomerism is a rare condition characterized by a bronchial structure on the right side that is a mirror image of the left side. In this report, we record our experience with a 62-year-old female lung cancer patient in whom left bronchial isomerism was discovered during surgery using a thoracoscope. A right upper pulmonary lobectomy was successfully completed, the key to which was successful separation of the right upper and middle lobes. As there is a risk of excising the wrong bronchi in such cases, thoracic surgeons need to identify bronchus variations...
October 17, 2016: Thoracic Cancer
https://www.readbyqxmd.com/read/27755803/comparative-study-of-three-dimensional-versus-two-dimensional-video-assisted-thoracoscopic-two-port-lobectomy
#8
Peng Jiao, Qing-Jun Wu, Yao-Guang Sun, Chao Ma, Wen-Xin Tian, Han-Bo Yu, Hong-Feng Tong
BACKGROUND: The advantages and disadvantages of three-dimensional (3D) and two-dimensional (2D) two-port video-assisted thoracoscopic surgery (VATS) lobectomy and systematic dissection of mediastinal lymph nodes for lung cancer were investigated. METHODS: Between December 2013 and July 2015 at Beijing Hospital, 191 patients underwent lobectomy and systematic dissection of mediastinal lymph nodes for lung cancer. After applying the study criteria, a total of 165 patients were included and allocated to 3D (n = 76) and 2D (n = 89) groups...
October 4, 2016: Thoracic Cancer
https://www.readbyqxmd.com/read/27755813/clinical-outcome-of-node-negative-oligometastatic-non-small-cell-lung-cancer
#9
Kiyohiro Sakai, Masayuki Takeda, Hidetoshi Hayashi, Kaoru Tanaka, Takeshi Okuda, Amami Kato, Yasumasa Nishimura, Tetsuya Mitsudomi, Atsuko Koyama, Kazuhiko Nakagawa
INTRODUCTION: The concept of "oligometastasis" has emerged as a basis on which to identify patients with stage IV non-small cell lung cancer (NSCLC) who might be most amenable to curative treatment. Limited data have been available regarding the survival of patients with node-negative oligometastatic NSCLC. PATIENTS AND METHODS: Consecutive patients with advanced NSCLC who attended Kindai University Hospital between January 2007 and January 2016 were recruited to this retrospective study...
September 12, 2016: Thoracic Cancer
https://www.readbyqxmd.com/read/27755806/diagnosis-of-a-rare-primary-pulmonary-synovial-sarcoma-with-endobronchial-ultrasound-guided-transbronchial-needle-aspiration
#10
Cai-Hua Wang, Chuan-Cai Xu, Jun-Hong Jiang, Yan-Bin Chen, Sheng-Hua Zhan
Primary pulmonary synovial sarcoma (PPSS) is a rare disease. Diagnosis is made postoperatively following resection of the tumor. We describe the case of a 39-year-old non-smoking woman whose chest imaging revealed a heterogeneous mass (5.4 cm × 4.6 cm), with soft tissue density in the right upper lobe and pleural effusion in the right hemithorax. The tumor was enhanced on a computed tomography scan, in which enlargement of the mediastinal lymph nodes compressing the adjacent superior vena cava was observed...
September 10, 2016: Thoracic Cancer
https://www.readbyqxmd.com/read/27807951/complete-remission-of-liver-metastasis-in-a-lung-cancer-patient-with-epidermal-growth-factor-mutation-achieved-with-icotinib
#11
Zhouyu Zhu, Ying Chai
A 65-year-old Chinese male was referred to our hospital for epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC). Aggressive combined therapy with surgical resection of the right upper lung lesion and chemotherapy was performed. One month later, continued Icotinib treatment was used as magnetic resonance imaging revealed liver metastasis (LM). Interestingly, complete remission of the patient's LM lesions was achieved in six months. To our knowledge, this is the first report documenting a successful case of an NSCLC patient with LM treated with Icotinib after receiving a radical resection for pulmonary carcinoma...
November 2016: Thoracic Cancer
https://www.readbyqxmd.com/read/27807950/acknowledgments
#12
(no author information available yet)
No abstract text is available yet for this article.
November 2016: Thoracic Cancer
https://www.readbyqxmd.com/read/27755835/effects-of-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitors-alone-on-egfr-mutant-non-small-cell-lung-cancer-with-brain-metastasis
#13
Qiuyi Zhang, Xuchao Zhang, Honghong Yan, Benyuan Jiang, Chongrui Xu, Jinji Yang, Zhihong Chen, Jian Su, Yi-Long Wu, Qing Zhou
BACKGROUND: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are remarkably effective for treating EGFR-mutant non-small cell lung cancer (NSCLC). However, the individual role of EGFR-TKIs in patients with brain metastasis (BM) arising from EGFR-mutant NSCLC remains unclear. METHODS: Patients with BM secondary to NSCLC and harboring EGFR-activating mutations were retrospectively screened. Patients who received gefitinib or erlotinib to control both extracranial lesions (ECLs) and intracranial lesions (ICLs) were eligible...
September 1, 2016: Thoracic Cancer
https://www.readbyqxmd.com/read/27755796/study-of-efficacy-and-safety-of-pulsatile-administration-of-high-dose-gefitinib-or-erlotinib-for-advanced-non-small-cell-lung-cancer-patients-with-secondary-drug-resistance-a-single-center-single-arm-phase-ii-clinical-trial
#14
Yanzhe Zhu, Yingying Du, Hu Liu, Tai Ma, Yuanyuan Shen, Yueyin Pan
BACKGROUND: The objective of the study was to observe the efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib in patients with advanced non-small cell lung cancer (NSCLC) with secondary drug resistance to standard doses of tyrosine kinase inhibitor (TKI) treatment. MATERIALS AND METHODS: We recruited 42 NSCLC patients from our hospital, between August 2014 and December 2015, who had experienced drug resistance after one year of conventional treatment with gefitinib or erlotinib...
November 2016: Thoracic Cancer
https://www.readbyqxmd.com/read/27755793/clinicopathological-characteristics-and-prognosis-of-resected-cases-of-carcinoid-tumors-of-the-lung
#15
Zhi Yang, Zitong Wang, Yong Duan, Shaofa Xu
BACKGROUND: Lung carcinoid tumors are rare, low-grade, malignant neoplasms with some unclear features. The aim of this study was to analyze clinicopathological features and long-term survival in patients with primary lung carcinoid tumors. METHODS: Patients who underwent surgery in our clinic and were diagnosed with carcinoid tumors, between August 1997 and July 2012, were included in the study. Patient characteristics and clinicopathological factors were retrospectively evaluated...
September 6, 2016: Thoracic Cancer
https://www.readbyqxmd.com/read/27766787/prognostic-factors-in-patients-after-definitive-chemoradiation-using-involved-field-radiotherapy-for-esophageal-cancer-in-a-phase-ii-study
#16
Hideomi Yamashita, Ryousuke Takenaka, Kae Okuma, Kuni Ootomo, Keiichi Nakagawa
BACKGROUND: A prospective study was performed on the use of chemoradiotherapy (CRT) for esophageal cancer (EC) with involved-field radiation therapy (IFRT), based on 18-fluorodeoxyglucose positron-emission tomography. Prognostic factors for overall survival (OS) were analyzed. METHODS: Eligible patients included 63 adults with newly diagnosed, untreated, inoperable stage I-IV EC with lymph node metastases. Patients received 80 mg/m(2) nedaplatin per day on day 1, 800 mg/m(2) 5-fluorouracil on days 1-4 intravenously repeated every 28 days for two to four cycles, and combined IFRT...
September 2016: Thoracic Cancer
https://www.readbyqxmd.com/read/27766786/cytopathological-findings-of-primary-pulmonary-ewing-family-of-tumors-with-ewsr1-translocation-a-case-report
#17
Keishi Mizuguchi, Hiroshi Minato, Hitomi Onishi, Yuki Mitani, Jun Kawai
Primary pulmonary neoplasms of the Ewing family of tumors (EFT) are extremely rare and usually occur in adolescents or young adults. Only about 40 cases of pulmonary EFT have been reported in English literature, and no cytological studies have been documented. In this report, we describe the cytopathological findings of a primary pulmonary EFT in an elderly patient. A 70-year-old man sought care because of a progressing cough and dyspnea. Chest computed tomography revealed a circumscribed mass of 6 cm in the left upper lobe...
September 2016: Thoracic Cancer
https://www.readbyqxmd.com/read/27766785/primary-pulmonary-angiosarcoma-three-case-reports-and-literature-review
#18
Yanhong Ren, Min Zhu, Yan Liu, Xiaoli Diao, Yuhui Zhang
Primary pulmonary angiosarcoma is a rare type of malignant vascular tumor with a very aggressive clinical course and a grim prognosis. To date, only a handful of cases have been reported in English literature. Its rarity and consequent low index of suspicion makes clinical diagnosis difficult. In this report we present three cases of primary pulmonary angiosarcoma with cough, hemoptysis, and progressive dyspnea to contribute to the sparse literature on this disease. A review is made of previous reports of primary pulmonary angiosarcomas, and the clinical characteristics, diagnosed method, treatment options, and prognosis of pulmonary angiosarcoma are also discussed...
September 2016: Thoracic Cancer
https://www.readbyqxmd.com/read/27766784/retrospective-study-of-adjuvant-icotinib-in-postoperative-lung-cancer-patients-harboring-epidermal-growth-factor-receptor-mutations
#19
Shuyang Yao, Xiuyi Zhi, Ruotian Wang, Kun Qian, Mu Hu, Yi Zhang
BACKGROUND: Epidermal growth factor receptor (EGFR) mutations occur in about 50% of Asian patients with non-small cell lung cancer (NSCLC). Patients with advanced NSCLC and EGFR mutations derive clinical benefit from treatment with EGFR-tyrosine kinase inhibitors (TKIs). This study assessed the efficacy and safety of adjuvant icotinib without chemotherapy in EGFR-mutated NSCLC patients undergoing resection of stage IB-IIIA. METHODS: Our retrospective study enrolled 20 patients treated with icotinib as adjuvant therapy...
September 2016: Thoracic Cancer
https://www.readbyqxmd.com/read/27766783/long-lasting-response-to-third-line-crizotinib-treatment-in-a-patient-with-non-small-cell-lung-cancer-with-brain-metastases-and-poor-performance-status
#20
De-Lan Li, Xin-Ru Chen, Shu-Xiang Ma, Li-Kun Chen
Identification of the anaplastic lymphoma kinase (ALK) gene has refined the classification of non-small cell lung cancer (NSCLC) and promoted research on molecularly targeted drugs such as crizotinib, an ALK inhibitor with good efficacy, in ALK-rearranged NSCLC. At present, few studies have reported the efficacy of crizotinib in patients with ALK-rearranged NSCLC with brain metastases. In a patient with NSCLC harboring ALK-rearrangement who had brain metastases and poor performance status (PS), we obtained a durable response with crizotinib administered following multi-line chemotherapy regimens...
September 2016: Thoracic Cancer
journal
journal
43030
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"